RxSight, Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against RxSight, Inc. (RXST).

If you purchased or held RxSight, Inc. securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About RxSight, Inc.

RxSight, Inc. is a medical technology company focused on developing and commercializing innovative solutions for vision correction. The company is known for its Light Adjustable Lens (LAL) system, which allows physicians to adjust and fine-tune lens power after cataract surgery.

RxSight operates in the ophthalmic device sector and serves eye care professionals and patients seeking advanced cataract treatment options. The company’s products and technology are designed to improve patient outcomes and offer flexibility in vision correction.

The Allegations

Investors are raising concerns about a series of statements and omissions made by RxSight, Inc. regarding its financial outlook and business performance. On Feb. 25, 2025, RxSight stated it was “reiterating guidance” for 2025 revenue of $185–197 million, suggesting continued strong growth. Later, on May 7, 2025, the company again “reiterated” guidance of $160–175 million, maintaining a positive outlook for investors.

However, after the market closed on July 8, 2025, RxSight issued a press release and held a call revealing that its second quarter 2025 revenue would be only about $33.6 million, which was approximately 4% below the prior year. Even more significantly, the company slashed its full-year 2025 guidance to $120–130 million, a dramatic reduction from earlier projections. This sharp revision was not previously disclosed to investors and coincided with a stock price plunge of about 33.8%, closing at approximately $8.47 compared to the prior close of around $12.79. With about 40.5 million shares outstanding, this one-day decline wiped out an estimated $170–$180 million in market value.

The July 8 disclosure also revealed that LDD device sales were only 40 units, representing a 49% year-over-year drop. This information had not been previously shared with investors, despite earlier positive statements about the company’s installed base and lens sales. The omission of these negative trends, coupled with the upbeat forecasts, rendered prior communications misleading.

Market data shows that on July 8, 2025, broad indexes were flat (Nasdaq up 0.1%, S&P 500 down 0.1%), indicating that RxSight’s stock drop was company-specific and triggered by its own disclosure, not broader market trends.

There are also questions about insider trades. In early 2025, directors sold stock at peak prices: Director Tamara Fountain sold 7,000 shares at about $25.71 on Mar. 12, 2025, and Director Shweta Maniar sold 3,519 shares at $30.87 on Jan. 22, 2025. These sizable sales occurred just months before the negative disclosure, at prices far above the post-drop trading range of $12–13.

The likely class period for affected investors is from Feb. 25, 2025, to July 8, 2025. During this time, investors who purchased RxSight common stock may have been misled by the company’s statements and omissions. The estimated market loss from the stock’s decline is substantial, with damages potentially running into the tens or even hundreds of millions of dollars for investors who purchased during this period.

Your Rights and Next Steps

As this is an active investigation, investors who purchased or held RxSight, Inc. securities between Feb. 25, 2025, and July 8, 2025, should be aware of their rights. If the investigation uncovers sufficient evidence of securities fraud, it may lead to a class action lawsuit seeking recovery for affected investors.

Investors are encouraged to gather documentation of their RxSight, Inc. purchases and sales, as these records may be important for any future claims. Lawyers are ready to help review individual situations and determine eligibility for participation in any potential class action. It is important to act promptly, as securities investigations and any resulting lawsuits are time-sensitive.

You May Be Entitled to Compensation

If you purchased RxSight, Inc. securities and suffered losses during the potential class period, you may be eligible to join this investigation and seek financial recovery. Securities investigations move quickly, and acting now can help preserve your rights.

To learn more and find out if you qualify, complete the below form to join the investigation.